Oligonucleotide and RNA-targeted therapeutics for chronic hepatitis B: Antigen reduction, delivery, and functional cure strategies
Related Experiment Video
Updated: Oct 31, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Xingchen Meng1,2, Faisal Mahmood1, Hui Li3
1Central Laboratory, Affiliated Hospital of Yunnan University, Kunming, Yunnan Province 650203, China.
Abstract:
Chronic hepatitis B (CHB) remains difficult to cure because nucleos(t)ide analogs suppress hepatitis B virus (HBV) replication but do not eliminate covalently closed circular DNA (cccDNA) or integrated HBV DNA, which sustain viral RNA and hepatitis B surface antigen (HBsAg) production. RNA-targeted therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and CRISPR-Cas13 platforms, offer sequence-directed approaches to suppress HBV transcripts and reduce antigen burden. Clinical evaluation of emerging HBV-directed therapies, including JNJ-3989, bepirovirsen, imdusiran, and related candidates, has demonstrated meaningful declines in circulating HBsAg levels. The recent phase III B-Well data further support the role of ASO-mediated antigen reduction as a potential therapeutic approach to increase the likelihood of functional cure within finite treatment regimens for selected patients. However, therapeutically induced HBsAg reduction alone rarely guarantees durable off-treatment control. This review summarizes HBV-directed RNA and oligonucleotide therapeutics from a translational pharmacology perspective, emphasizing transcript-silencing mechanisms, delivery constraints, pharmacodynamic endpoints, safety considerations, biomarker-guided patient selection, and integration with nucleos(t)ide analogs and immunomodulatory interventions. We propose that RNA-mediated antigen reduction may support finite therapy in biomarker-selected patients and may also serve as an antigen-conditioning component within staged functional cure strategies.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Viruses with RNA Genomes
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
